Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? [Yahoo! Finance]
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Yahoo! Finance
price target on Nuvation Bio Inc. (NYSE:NUVB) from $6 to $8 and kept its Market Outperform rating. This decision came after the company reported Q3 results. Citizens highlighted that Nuvation Bio Inc. (NYSE:NUVB) successfully started 204 patients on IBTROZI (taletrectinib) in the third quarter of 2025. This launch is exceeding expectations and outpacing other recent ROS1 inhibitor launches. Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? IBTROZI (taletrectinib) is Nuvation Bio Inc.'s (NYSE:NUVB) next-generation inhibitor for ROS1-positive non-small cell lung cancer. Updated data has demonstrated that IBTROZI (taletrectinib) is continuing to show unprecedented durability. Because of IBTROZI's (taletrectinib) impressive performance, Citizens has raised its short-term forecasts for Nuvation Bio Inc. (NYSE:NUVB). Nuvation Bio Inc. (NYSE:NUVB) is a biopharmaceutical company focused on developing oncology therapeutics. While we acknowledge the potential of N
Show less
Read more
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result [Yahoo! Finance]Yahoo! Finance
- Lenz Therapeutics: A Close Look [Seeking Alpha]Seeking Alpha
- Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]Seeking Alpha
- Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-OncologyBusiness Wire
- Nuvation Bio (NYSE:NUVB) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
NUVB
Earnings
- 11/3/25 - Beat
NUVB
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/26/25 - Form 4
- NUVB's page on the SEC website